Investing.com - Axcelis (NASDAQ: ACLS) reported second quarter EPS of $1.55, $0.18 better than the analyst estimate of $1.37. Revenue for the quarter came in at $256.5M versus the consensus estimate of $250.06M.
Guidance
Axcelis sees Q3 2024 EPS of $1.43 versus the analyst consensus of $1.50.
Axcelis sees Q3 2024 revenue of $255.00M versus the analyst consensus of $261.90M.
Axcelis's stock price closed at $126.35. It is up 13.37% in the last 3 months and down -35.60% in the last 12 months.
Axcelis saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Axcelis's stock price’s past reactions to earnings here.
According to InvestingPro, Axcelis's Financial Health score is "great performance".
Check out Axcelis's recent earnings performance, and Axcelis's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Is ACLS truely undervalued?
With ACLS making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed ACLS alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? ACLS wasn't at the top of the list.
Unlock ProPicks AI